Last reviewed · How we verify
Cafusertib Hydrochloride — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Cafusertib Hydrochloride (Cafusertib Hydrochloride) — Jiangsu Hansoh Pharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cafusertib Hydrochloride TARGET | Cafusertib Hydrochloride | Jiangsu Hansoh Pharmaceutical Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cafusertib Hydrochloride CI watch — RSS
- Cafusertib Hydrochloride CI watch — Atom
- Cafusertib Hydrochloride CI watch — JSON
- Cafusertib Hydrochloride alone — RSS
Cite this brief
Drug Landscape (2026). Cafusertib Hydrochloride — Competitive Intelligence Brief. https://druglandscape.com/ci/cafusertib-hydrochloride. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing